Esperion Reaches Deal With TransGenRx

Xconomy Detroit/Ann Arbor — 

Esperion Therapeutics, a biopharmaceutical company based in Ann Arbor, MI, has announced that TransGenRx, a Baton Rouge, LA, company, will produce protein-based therapeutics to be used in Esperion’s research. Esperion is developing therapies to treat cardio-metabolic disease including therapies based on HDL, the body’s “good” cholesterol, which has been shown to play an important role in lipid management. TransGenRx will coordinate production of protein-based therapies. “While HDL continues to show great promise in the treatment of cardiovascular disease, there have been significant challenges in the development of protein-based drug therapies, Roger Newton, Esperion’s president and CEO, said in a prepared statement.